

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

References

- Aliberti S, Peyrani P, Filardo G et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. *Chest*. 2011; 140:482-8.
- Andrews RM, Elixhauser A. The national hospital bill: growth trends and 2005 update on the most expensive conditions by payer. Rockville, MD: Agency for Healthcare Research and Quality; 2007 Dec.
- Arancibia F, Ewig S, Martinez JA et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. *Am J Respir Crit Care Med*. 2000; 162:154-60.
- Avdic E, Cushinotto LA, Hughes AH et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. *Clin Infect Dis*. 2012; 54:1581-7.
- Baddour LM. Cellulitis and erysipelas. In Basow DS, ed. UpToDate. http://www.uptodate.com/contents/cellulitis-and-erysipelas?detectedLanguage=en&source=search_result&search=cellulitis&selectedTitle=1%7E150&provider=noProvider (accessed 2013 Nov 13).
- Baker DW, Einstadter D, Husak SS et al. Trends in postdischarge mortality and readmissions: has length of stay declined too far. *Arch Intern Med*. 2004; 164:538-44.
- Basilea Pharmaceutica Ltd press release. Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia. October 23, 2013. <http://online.wsj.com/article/PR-CO-20131023-900186.html> (accessed 2013 Nov 13).
- Bridges CB, Woods L, Coyne-Beasley T et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older—United States, 2013. *MMWR Surveill Summ*. 2013; 62:9-19. <http://1.usa.gov/13EDI0e> (accessed 2013 Nov 13).
- Brown KA, Khanafer N, Daneman N et al. Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother*. 2013; 57:2326-32.
- Capelastegui A, Espana Yandiola PP, Quintana JM et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. *Chest*. 2009; 136:1079-85.
- Carratala J, Garcia-Vidal C, Ortega L et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. *Arch Intern Med*. 2012; 172:922-8.
- Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2012; 61(40):816-9.

www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm (accessed 2013 Nov 13)

Centers for Medicare & Medicaid Services. Hospital Compare database.

<http://www.medicare.gov/hospitalcompare/?AspxAutoDetectCookieSupport=1> (accessed 2013 Nov 13)

Centers for Medicare & Medicaid Services. The Joint Commission. Pneumonia Measures. November 2011. <http://www.jointcommission.org/pneumonia/> (accessed 2013 Nov 13)

Centers for Medicare & Medicaid Services. The Joint Commission. Specifications manual for national hospital inpatient quality measures. Version 4.3a for discharges 01/01/2014 to 09/30/2014. October 2013.

<http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228773265583> (accessed 2013 Nov 13).

Choi SH, Hong SB, Ko GB et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. *Am J Respir Crit Care Med.* 2012; 186:325-32.

Clinical Resource Efficiency Support Team (CREST). CREST guidelines on the management of cellulitis in adults. DHSS Northern Ireland; 2005:1-31. Available at:

<http://www.acutemed.co.uk/docs/Cellulitis%20guidelines,%20CREST,%2005.pdf> (accessed 2013 Nov 13).

Clinicaltrials.gov database. Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infections. Identifier NCT01339091.

<http://clinicaltrials.gov/ct2/show/NCT01339091> (accessed 2013 Nov 13).

Clinicaltrials.gov database. Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infections. Identifier NCT01431339

<http://clinicaltrials.gov/ct2/show/NCT01431339> (accessed 2013 Nov 13).

Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. *Clin Infect Dis.* 2011; 52(Suppl 7):S469-76.

Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. *Clin Infect Dis.* 2010; 51:641-50.

Corey GR, Wilcox MH, Talbot GH et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. *J Antimicrob Chemother.* 2010; 65(Suppl 4):iv41-51.

Critchley IA, Eckburg PB, Jandourek A et al. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. *J Antimicrob Chemother.* 2011; 66(Suppl 3):iii45-51.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

- Deresinski SC. Ceftobiprole: breaking therapeutic dogmas of the beta-lactam class. *Diagn Microbiol Infect Dis*. 2008; 61:82-5.
- Dimopoulos G, Matthaïou DK, Karageorgopoulos DE et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. *Drugs*. 2008; 68:1841-54.
- Doernberg SB, Winston LG, Deck DH et al. Does doxycycline protect against development of *Clostridium difficile* infection? *Clin Infect Dis*. 2012; 55:615-20.
- Dryden M, Saeed K, Townsend R et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. *J Antimicrob Chemother*. 2012; 67:2289-96.
- Duong M, Markwell S, Peter J et al. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. *Ann Emerg Med*. 2010; 55:401-7.
- Ebell MH. Outpatient vs. inpatient treatment of community acquired pneumonia. *Fam Pract Manag*. 2006; 13:41-4.
- Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. *Eur J Med Res*. 2010; 15:554-63.
- Edelsberg J, Taneja C, Zervos M et al. Trends in US hospital admissions for skin and soft tissue infections. *Emerg Infect Dis*. 2009; 15:1516-8.
- Edelsberg J, Berger A, Weber DJ et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. *Infect Control Hosp Epidemiol*. 2008; 29:160-9.
- Elliott DJ, Zaoutis TE, Troxel AB et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant *Staphylococcus aureus*. *Pediatrics*. 2009; 123:e959-66.
- el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. *BMJ*. 2006; 332:1355.
- Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with *Staphylococcus aureus* surgical site infection. *Clin Infect Dis*. 2003; 36:592-8.
- English ML, Fredericks CE, Milanese NA et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. *Antimicrob Agents Chemother*. 2012; 56:2037-47.
- Epstein AM, Jha AK, Oray EJ. The relationship between hospital admission rates and rehospitalizations. *N Engl J Med*. 2011; 365:2287-95.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

- Farrell DJ, Flamm RK, Jones RN et al. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). *Diagn Microbiol Infect Dis*. 2013; 75:86-8.
- Ferrer M, Menendez R, Amaro R et al. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. *Clin Chest Med*. 2011; 32:491-505.
- File TM Jr, Solomkin JS, Cosgrove SE. Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs. *Clin Infect Dis*. 2011; 53(Suppl 1):S15-22.
- File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. *Postgrad Med*. 2010; 122:130-41.
- File TM Jr. Community-acquired pneumonia. *Lancet*. 2003; 362:1991-2001.
- File TM Jr. Clinical implications and treatment of multiresistant *Streptococcus pneumoniae* pneumonia. *Clin Microbiol Infect*. 2006; 12(Suppl 3):31-41.
- File TM Jr, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. *Clin Infect Dis*. 2010; 51:1395-405.
- File TM Jr. The science of selecting antimicrobials for community-acquired pneumonia (CAP). *J Manag Care Pharm*. 2009; 15(2 Suppl):S5-11.
- Friedland HD, O'Neal T, Biek D et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. *Antimicrob Agents Chemother*. 2012; 56:2231-6.
- Gunderson CG. Cellulitis: definition, etiology, and clinical features. *Am J Med*. 2011; 124:1113-22.
- Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. *J Infect*. 2012; 65:128-34.
- Huijskens EG, Rossen JW, Kluytmans JA et al. Evaluation of yield of currently available diagnostics by sample type to optimize detection of respiratory pathogens in patients with a community-acquired pneumonia. *Influenza Other Respir Viruses*. 2013 Aug 20. [Epub ahead of print]
- Irfan M, Farooqi J, Hasan R et al. Community-acquired pneumonia. *Curr Opin Pulm Med*. 2013; 19:198-208.
- Jasti H, Mortensen EM, Obrosky DS et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. *Clin Infect Dis*. 2008; 46:550-6.
- Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. *Clin Infect Dis*. 2005; 41:1407-15.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

- Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med*. 2009; 360:1418-28.
- Jeng A, Beheshti M, Li J et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. *Medicine (Baltimore)*. 2010; 89:217-26.
- Jenkins TC, Sakai J, Knepper BC et al. Risk factors for drug-resistant *Streptococcus pneumoniae* and antibiotic prescribing practices in outpatient community-acquired pneumonia. *Acad Emerg Med*. 2012; 19:703-6.
- Johansson N, Kalin M, Tiveljung-Lindell A et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. *Clin Infect Dis*. 2010; 50:202-9.
- Kallen AJ, Brunkard J, Moore Z et al. *Staphylococcus aureus* community-acquired pneumonia during the 2006 to 2007 influenza season. *Ann Emerg Med*. 2009; 53:358-65.
- Kanwar M, Brar N, Khatib R et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. *Chest*. 2007; 131:1865-9.
- Karampela I, Poulakou G, Dimopoulos G. Community acquired methicillin resistant *Staphylococcus aureus* pneumonia: an update for the emergency and intensive care physician. *Minerva Anesthesiol*. 2012; 78:930-40.
- Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant *Staphylococcus aureus*, United States, 1999-2005. *Emerg Infect Dis*. 2007; 13:1840-6.
- Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest*. 1999; 115:462-74.
- Liapikou A, Torres A. Current treatment of community-acquired pneumonia. *Expert Opin Pharmacother*. 2013; 14:1319-32.
- Lim WS. Severity assessment in community-acquired pneumonia: moving on. *Thorax*. 2007; 62:287-8.
- Lipsky BA, Berendt AR, Cornia PB et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2012; 54:e132-73.
- Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011; 52:e18-55.
- Lodise TP, McKinnon PS, Tam VH et al. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. *Clin Infect Dis*. 2002; 34:922-9.
- Love BL. Management of complicated skin and soft tissue infections in hospitalized patients. *US Pharm*. 2007; 32(4):HS5-HS12.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

http://www.uspharmacist.com/content/c/10354/?t=men's_health,dermatology (accessed 2013 Nov 13).

Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007; 44(Suppl 2):S27-72.

Marwick C, Broomhall J, McCowan C et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. *J Antimicrob Chemother*. 2011; 66:387-97.

Marwick C, Rae N, Irvine N et al. Prospective study of severity assessment and management of acute medical admissions with skin and soft tissue infection. *J Antimicrob Chemother*. 2012; 67:1016-9.

Medicare Payment Advisory Commission (MedPAC). Report to Congress: promoting greater efficiency in Medicare. Medicare Payment Advisory Commission (MedPAC); 2007.

Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. *JAMA*. 1997; 278:2080-4.

Menendez R, Torres A, Rodriguez de Castro F et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. *Clin Infect Dis*. 2004; 39:1783-90.

Menzin J, Marton JP, Meyers JL et al. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of *Staphylococcus aureus*. *Am J Infect Control*. 2010; 38:44-9.

Metersky ML, Waterer G, Nsa W et al. Predictors of in-hospital vs postdischarge mortality in pneumonia. *Chest*. 2012; 142:476-81.

Metersky ML, Ma A, Bratzler DW et al. Predicting bacteremia in patients with community-acquired pneumonia. *Am J Respir Crit Care Med*. 2004; 169:342-7.

Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N Engl J Med*. 2006; 355:666-74.

Moran GJ, Krishnadasan A, Gorwitz RJ et al. Prevalence of methicillin-resistant *Staphylococcus aureus* as an etiology of community-acquired pneumonia. *Clin Infect Dis*. 2012; 54:1126-33.

Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. *Med Clin North Am*. 2011; 95:1143-61.

Nicholson SC, Welte T, File TM Jr et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. *Int J Antimicrob Agents*. 2012; 39:240-6.

Paterson R, MacLeod DC, Thetford D et al. Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. *Clin Med*. 2006; 6:281-4.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

Pfaller MA, Farrell DJ, Sader HS et al. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* in the United States. *Clin Infect Dis*. 2012; 55(Suppl 3):S187-93.

Prokocimer P, De Anda C, Fang E et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. *JAMA*. 2013; 309:559-69.

Radigan E, Capistran C, Zivna I et al. Clinical impact of a positive pneumococcal urinary antigen test (UAT) on antimicrobial therapy (AT): a stewardship opportunity? Poster presented at ID Week. San Diego, CA: October 19, 2012. Abstract 733.
<https://idsa.confex.com/idsa/2012/webprogram/Paper36877.html> (accessed 2013 Nov 13).

Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. *Cleve Clin J Med*. 2012; 79:57-66.

Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired *Streptococcus pneumoniae* pneumonia. *Arch Intern Med*. 2001; 161:848-50.

Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. *N Engl J Med*. 2012; 366:1881-90.

Roson B, Carratala J, Dorca J et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. *Clin Infect Dis*. 2001; 33:158-65.

Sader HS, Mallick R, Kuznik A et al. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. *Int J Antimicrob Agents*. 2007; 30:514-20.

Scalera NM, File TM Jr. Determining the duration of therapy for patients with community-acquired pneumonia. *Curr Infect Dis Rep*. 2013; 15:191-5.

Schmitz GR, Bruner D, Pitotti R et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant *Staphylococcus aureus* infection. *Ann Emerg Med*. 2010; 56:283-7.

Shorr AF, Zilberberg MD, Reichley R et al. Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals. *Clin Infect Dis*. 2013; 57:362-7.

Shorr AF, Kollef M, Eckburg PB et al. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to *Streptococcus pneumoniae*: insights from two randomized trials. *Diagn Microbiol Infect Dis*. 2013; 75:298-303.

Sibila O, Restrepo MI, Anzueto A. What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents). *Infect Dis Clin North Am*. 2013; 27:133-47.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

Song X, Srinivasan A, Plaut D et al. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. *Infect Control Hosp Epidemiol.* 2003; 24:251-6.

Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. *Clin Infect Dis.* 2008; 46:1683-93.

Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. *N Engl J Med.* 2013; 368:1704-12.

Teflaro (ceftaroline fosamil) prescribing information. St Louis, MO: Forest Pharmaceuticals, Inc.; 2013 Jul.

Tognetti L, Martinelli C, Berti S et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. *J Eur Acad Dermatol Venereol.* 2012; 26:931-41.

Toubes E, Singh K, Yin D et al. Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? *Clin Infect Dis.* 2003; 36:724-30.

U.S. Department of Health and Human Services. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment.

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf> (accessed 2013 Nov 13).

U.S. Department of Health and Human Services. Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. March 2009 draft guidance.

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm123686.pdf> (accessed 2013 Nov 13).

U.S. Food and Drug Administration. FDA approves Vibativ for hospitalized patients with bacterial pneumonia. June 21, 2013.

<http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm358209.htm> (accessed 2013 Nov 13).

U.S. Food and Drug Administration. Tygacil (tigecycline): drug safety communication—increased risk of death. September 27, 2013.

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm370170.htm> (accessed 2013 Nov 13).

U.S. Food and Drug Administration. FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning.

September 27, 2013. <http://www.fda.gov/drugs/drugsafety/ucm369580.htm> (accessed 2013 Nov 13).

van Rensburg DJ, Perng RP, Mitha IH et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. *Antimicrob Agents Chemother.* 2010; 54:4098-106.

Applying Antimicrobial Stewardship Principles to the Treatment of CABP and ABSSSI: Complying with CMS Criteria and Clinical Guidelines

Vecchiarino P, Bohannon RW, Ferullo J et al. Short-term outcomes and their predictors for patients hospitalized with community-acquired pneumonia. *Heart Lung*. 2004; 33:301-7.

Vibativ (telavancin) prescribing information. South San Francisco, CA: Theravance, Inc; 2013 Jun.

Wilcox MH, Corey GR, Talbot GH et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. *J Antimicrob Chemother*. 2010; 65(Suppl 4):iv53-iv65.

Wilson KC, Schunemann HJ. An appraisal of the evidence underlying performance measures for community-acquired pneumonia. *Am J Respir Crit Care Med*. 2011; 183:1454-62.

Wroe PC, Finkelstein JA, Ray GT et al. Aging population and future burden of pneumococcal pneumonia in the United States. *J Infect Dis*. 2012; 205:1589-92.

Wunderink RG. How important is methicillin-resistant *Staphylococcus aureus* as a cause of community-acquired pneumonia and what is best antimicrobial therapy? *Infect Dis Clin North Am*. 2013; 27:177-88.

Zilberberg MD, Chaudhari P, Nathanson BH et al. Development and validation of a bedside risk score for MRSA among patients hospitalized with complicated skin and skin structure infections. *BMC Infect Dis*. 2012; 12:154.

Other Resources

QualityNet website
www.qualitynet.org/

Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis*. 2005; 41:1373-406.